Laboratory-Developed Tests - Medical devices 2017

  • Check with publisher
  • Published date: June 14, 2017
    • Fremont, California, United States

Overview:
This presentation will review the legal definition of medical device, and how it is applied by FDA to in vitro diagnostic tests. It will review the history of FDA interest in LDTs, and will describe the current situation with respect to Laboratory-developed tests.

Why should you Attend:
This 1 hour session will explore the reasons FDA has for claiming such jurisdiction, and the objections to FDAs' position articulated by the clinical laboratory community, and others.

Areas Covered in the Session:
"Enforcement Discretion" and how it has been applied to LDT regulation
Extent of CLIA '88 authority over LDT performance
Role of US Congress in answering the question of FDA authority
International (EU) approach to LDTs

Who Will Benefit:
QA Specialist
Complaint Coordinator
Regulatory Specialist
QA Manager
QA Trainer
All above in Medical Device companies

Speaker Profile:
Anna Longwell is currently principal attorney of the Palo Alto Law firm, Longwell and Associates, which specializes in Food and Drug law. The firm has expertise in US FDA expectations, regulation and law, affecting the development and ultimate marketing of new medical products, drugs, devices and biologics. They have served the regulatory needs of large (>$2 billion/year) divisions of Fortune 500 companies, and small (4 person) biotech start-ups.

Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com

Full Details & Registration Link:
http://www.compliance4all.com/control/w_product/~product_id=501419LIVE?channel=marketplace_Aug_2017_SEO

Compliance4All
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-E. faecalis Therapeutic Antibody

    Anti-E. faecalis Therapeutic Antibody

    Biomedical Sciences Shirley (New York) November 20, 2017 Check with publisher

    This antibody generated to the E. faecalis antigens can potentially be used in diagnostic assays. http://www.creativebiolabs.net/Anti-E-faecalis-Therapeutic-Antibody-44542.htm

  • 483 Covers a Broad Gradation of Problems

    483 Covers a Broad Gradation of Problems

    Biomedical Sciences Fremont (California) August 14, 2017 Check with publisher

    Overview: How you respond to the 483 should provide the foundation for any future communication with the FDA about a particular inspection. Understanding how FDA organizes its evaluation of the 483 can facilitate the FDA’s review in your favor as it ...

  • Clinical Trials - Medical Device FDA's Program 2017

    Clinical Trials - Medical Device FDA's Program 2017

    Biomedical Sciences Fremont (California) June 14, 2017 Check with publisher

    Overview: The topic is device clinical trials. This term refers to the use of medical products on/in humans, in order to gain useful knowledge about the product. Why should you Attend: In spite of the long experience device companies have with clinic...